



## Publications

### Clinical Implementation of CYP2C19-Clopidogrel Testing

Last Updated April 5, 2018

1. Lee CR, Sriramoju VB, Cervantes A, Howell LA, Varunok N, Madan S, Hamrick K, Polasek MJ, Lee JA, Clarke M, Cicci JD, Weck KE, Stouffer GA. Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. *Circ Genom Precis Med*. 2018 Apr;11(4):e002069. Doi: 10.1161/CIRCGEN.117.002069. Pubmed PMID: 29615454.
2. Cavallari LH, Lee CR, Beitelshes AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh IS, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA; IGNITE Network. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. *JACC Cardiovasc Interv*. 2018 Jan 22;11(2):181-191. doi: 10.1016/j.jcin.2017.07.022. Epub 2017 Nov 1. PubMed PMID: 29102571; PubMed Central PMCID: PMC5775044.
3. Empey PE, Stevenson JM, Tuteja S, Weitzel KW, Angiolillo DJ, Beitelshes AL, Coons JC, Duarte JD, Franchi F, Jeng LJB, Johnson JA, Kreutz RP, Limdi NA, Maloney KA, Owusu Obeng A, Peterson JF, Petry N, Pratt VM, Rollini F, Scott SA, Skaar TC, Vesely MR, Stouffer GA, Wilke RA, Cavallari LH, Lee CR; IGNITE Network. Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy. *Clin Pharmacol Ther*. 2017 Dec 26. doi:10.1002/cpt.1006. [Epub ahead of print] PubMed PMID: 29280137.
4. Harada S, Zhou Y, Duncan S, Armstead AR, Coshatt GM, Dillon C, Brott BC, Willig J, Alsip JA, Hillegass WB, Limdi NA. Precision Medicine at the University of Alabama at Birmingham: Laying the foundational processes through implementation of Genotype-Guided Antiplatelet Therapy. *Clin Pharmacol Ther*. 2017 Sep;102(3):493-501. doi: 10.1002/cpt.631. Review. PubMed PMID: 28124392.
5. Cavallari LH, Lee CR, Duarte JD, Nutescu EA, Weitzel KW, Stouffer GA, Johnson JA. Implementation of inpatient models of pharmacogenetics programs. *Am J Health Syst Pharm*. 2016 Dec 1;73(23):1944-1954. PubMed PMID: 27864202.
6. Schildcrout JS, Shi Y, Danciu I, Bowton E, Field JR, Pulley JM, Basford MA, Gregg W, Cowan JD, Harrell FE Jr, Roden DM, Peterson JF, Denny JC. A prognostic model based on readily available clinical data enriched a pre-emptive pharmacogenetic testing program. *J Clin Epidemiol*. 2016 Apr;72:107-15. doi:10.1016/j.jclinepi.2015.08.028. PubMed PMID: 26628336; PubMed Central PMCID: PMC4779720.
7. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, Hunkler RJ, Klein TE, Evans WE, Relling MV. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. *Annu Rev Pharmacol Toxicol*. 2015;55:89-106. doi: 10.1146/annurev-pharmtox-010814-124835. Review. PubMed PMID: 25292429; PubMed Central PMCID: PMC4607278.
8. Lee JA, Lee CR, Reed BN, Plitt DC, Polasek MJ, Howell LA, Cicci JD, Tasca KE, Weck KE, Rossi JS, Stouffer GA. Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. *Pharmacogenomics*. 2015;16(4):303-13. doi: 10.2217/pgs.14.180. PubMed PMID: 25823779.
9. Owusu-Obeng A, Weitzel KW, Hatton RC, Staley BJ, Ashton J, Cooper-Dehoff RM, Johnson JA. Emerging roles for pharmacists in clinical implementation of pharmacogenomics. *Pharmacotherapy*. 2014 Oct;34(10):1102-12. doi: 10.1002/phar.1481. Review. PubMed PMID: 25220280; PubMed Central PMCID: PMC4188772.
10. Shuldiner AR, Palmer K, Pakyz RE, Alestock TD, Maloney KA, O'Neill C, Bhatti S, Schub J, Overby CL, Horenstein RB, Pollin TI, Kelemen MD, Beitelshes AL, Robinson SW, Blitzer MG, McArdle PF, Brown L, Jeng LJ, Zhao RY, Ambulos N,

Vesely MR. Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. *Am J Med Genet C Semin Med Genet.* 2014 Mar;166C(1):76-84. doi: 10.1002/ajmg.c.31396. PubMed PMID: 24616408; PubMed Central PMCID: PMC4066997.

11. Weitzel KW, Elsey AR, Langaee TY, Burkley B, Nessler DR, Obeng AO, Staley BJ, Dong HJ, Allan RW, Liu JF, Cooper-Dehoff RM, Anderson RD, Conlon M, Clare-Salzler MJ, Nelson DR, Johnson JA. Clinical pharmacogenetics implementation: approaches, successes, and challenges. *Am J Med Genet C Semin Med Genet.* 2014 Mar;166C(1):56-67. doi: 10.1002/ajmg.c.31390. PubMed PMID: 24616371; PubMed Central PMCID: PMC4076109.
12. Hoffman JM, Haidar CE, Wilkinson MR, Crews KR, Baker DK, Kornegay NM, Yang W, Pui CH, Reiss UM, Gaur AH, Howard SC, Evans WE, Broeckel U, Relling MV. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. *Am J Med Genet C Semin Med Genet.* 2014 Mar;166C(1):45-55. doi: 10.1002/ajmg.c.31391. PubMed PMID: 24619595; PubMed Central PMCID: PMC4056586.
13. Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, Delaney JT, Bowton E, Brothers K, Johnson K, Crawford DC, Schildcrout J, Masys DR, Dilks HH, Wilke RA, Clayton EW, Shultz E, Laposata M, McPherson J, Jirjis JN, Roden DM. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. *Clin Pharmacol Ther.* 2012 Jul;92(1):87-95. doi: 10.1038/clpt.2011.371. PubMed PMID: 22588608; PubMed Central PMCID: PMC3581305.